Assessment of bleeding events in clinical trials--proposal of a new classification.

[1]  S. Yusuf,et al.  Effects of Aspirin Dose When Used Alone or in Combination With Clopidogrel in Patients With Acute Coronary Syndromes: Observations From the Clopidogrel in Unstable angina to prevent Recurrent Events (CURE) Study , 2003, Circulation.

[2]  E F Cook,et al.  Identification and preliminary validation of predictors of major bleeding in hospitalized patients starting anticoagulant therapy. , 1987, The American journal of medicine.

[3]  H. Diener,et al.  Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial , 2004, The Lancet.

[4]  D. Sane,et al.  Risk of bleeding complications with antiplatelet agents: Meta‐analysis of 338,191 patients enrolled in 50 randomized controlled trials , 2004, American journal of hematology.

[5]  M. Keltai,et al.  Angiographic and Clinical Outcomes in Patients Receiving Low-Molecular-Weight Heparin Versus Unfractionated Heparin in ST-Elevation Myocardial Infarction Treated With Fibrinolytics in the CLARITY-TIMI 28 Trial , 2005, Circulation.

[6]  Frans Van de Werf,et al.  An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. , 1993, The New England journal of medicine.

[7]  A. Siegbahn,et al.  Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease. , 2006, European heart journal.

[8]  R. Collins,et al.  Addition of clopidogrel to aspirin in 45 852 patients with acute myocardial infarction: randomised placebo-controlled trial , 2005, The Lancet.

[9]  Eric J Topol,et al.  Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. , 2002, JAMA.

[10]  D. Atar,et al.  Noncompliance in cardiovascular clinical trials. , 2005, American heart journal.

[11]  Patrice Cacoub,et al.  Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. , 2006, The New England journal of medicine.

[12]  E. Antman,et al.  Randomized Comparison of Prasugrel (CS-747, LY640315), a Novel Thienopyridine P2Y12 Antagonist, With Clopidogrel in Percutaneous Coronary Intervention: Results of the Joint Utilization of Medications to Block Platelets Optimally (JUMBO)–TIMI 26 Trial , 2005, Circulation.

[13]  J. Blankenship.  Bleeding complications of glycoprotein IIb-IIIa receptor inhibitors. , 1999, American heart journal.

[14]  A. Jaffe,et al.  Thrombolysis in myocardial infarction (TIMI) trial—Phase I: Hemorrhagic manifestations and changes in plasma fibrinogen and the fibrinolytic system in patients treated with recombinant tissue plasminogen activator and streptokinase , 1988 .